Clinical characteristics of patients hospitalized for COVID-19 vaccinated with at least two doses in a tertiary care hospital in Turkey

Background. We aimed to examine the characteristics of Turkish patients hospitalized with COVID-19 despite being fully vaccinated. Method. A retrospective, single-center study was conducted in fully vaccinated patients with inactivated whole virion (CoronaVac) and/or BNT162b2 mRNA (Pfizer-BioNTech) vaccines and admitted to the hospital. We evaluated the hospitalized patients regarding the intensive care unit admission and death. A multivariate binary logistic regression analysis was used to determine the factors for mortality. Results. We conducted the study with 541 patients. The mean age was 70.2, and 52.1% of the patients were women. 73.6% of the patients were 65 years or older. The most common comorbidities were hypertension, diabetes mellitus, and COPD. The rate of the alpha variant was 54.3%, and the delta variant was 29.4%. The mortality rate was 45.8%, and the ICU admission rate was 55.3%. The delta (B.1.617.2) variant had higher ICU admission and mortality rate. Patients vaccinated with two-dose Sinovac-CoronaVac had a higher mortality rate. There was no difference between the time between the last vaccination dose to hospitalization, ICU admission, and mortality. LOS in the hospital was longer in ICU and mortality patients. In multivariate binary logistic analysis; age (odds ratio (OR), 1.06; 95% confidence intervals (95% CI) 1.04-1.08- year increase), male gender (OR, 1.57; 95% CI, 1.04-2.38), presence of comorbid diseases (OR, 4; 95% CI, 2-8) and delta variant (OR, 7.3; 95% CI, 4.4- 12.2) and vaccination with CoronaVac plus BioNTech (OR, 0.21; 95% CI, 0.07-0.62) were associated with death. Conclusion. Our results suggest administering a third and fourth dose of mRNA vaccine to subjects vaccinated primarily with two doses of CoronaVac

Objective Evaluation of Smell and Taste Senses in COVID-19 Patients

Objective:The severe acute respiratory syndrome‐coronavirus‐2 pandemic is one of the largest of the recent times and can cause many symptoms including smell and taste disorders. In the literature, smell disorders caused by coronavirus disease-2019 (COVID-19) have been reported within a wide range from 3.2% to 98.3%. A small number of these studies demonstrated smell and taste disorders through objective tests. Our aim in this study was to determine the prevalence of smell and taste disorders in hospitalized patients due to COVID-19 infection.Methods:The study was carried out with 100 patients who were positive for real-time polymerase chain reaction and treated at the Kayseri City Hospital, and 100 healthcare worker relatives. We used the Connecticut Chemosensory Clinical Research Center test to evaluate the sense of smell. Sense of taste was evaluated using four different standardized bottles of preparations, and the results were scored according to the patients’ statements.Results:Patient (Group 1) and control (Group 2) groups were compared for age, gender, smell and taste disorders. There were 39 women and 61 men in the patient group, and 40 women and 60 men in the control group. Mean age was 50.2±1.37 (range 21–70) years in Group 1 and 47.6±1.25 (range 18–70) years in Group 2, and there was no significant difference between the two groups. While the rate of smell disorder was 80% in Group 1, we found this rate as 35% in Group 2. Taste disturbance was identified in 38 patients, of whom 16 had mild hypogeusia, 17 had moderate hypogeusia, four had severe hypogeusia, and one patient had ageusia. We found that taste disorder was 38% in Group 1 and 3% in Group 2.Conclusion:Smell and taste dysfunctions are very common symptoms in COVID-19 patients. The results obtained using objective test methods are higher than the rates obtained from patient statements

Cryobiology and Cryopreservation of Sperm

Low temperature has been utilized to keep living cells and tissues dormant but potentially alive for cryopreservation and biobanking with great impacts on scientific and biomedical applications. However, there is a critical contradiction between the purpose of the cryopreservation and experimental findings: the cryopreserved cells and tissues can be fatally damaged by the cryopreservation process itself. Contrary to popular belief, the challenge to the life of living cells and tissues during the cryopreservation is not their ability to endure storage at cryogenic temperatures (below −190°C); rather it is the lethality associated with mass and energy transport within an intermediate zone of low temperature (−15 to −130°C) that a cell must traverse twice, once during cooling and once during warming. This chapter will focus on (1) the mechanisms of cryoinjury and cryopretection of human sperm in cryopreservation, and (2) cryopreservation techniques and methods developed based on the understanding of the above mechanisms

Seroprevalence of SARS COV-2 anti-nucleocapsid antibodies in Turkish healthcare workers before vaccination schedule: January 2021

Objective: We aimed to assess the seroprevalence of SARS-CoV-2 infection and associated factors among Turkish HCWs, before the Covid-19 vaccination program in January 2021. Material and methods: We performed antibody assessment against SARS-CoV-2 in blood samples from participants using the Elecsys® Anti-SARS-CoV-2 electrochemiluminescence immunoassay. Samples with a cut-off index (COI; signal sample/cut-off) <1.0 were considered negative, samples with ≥1.0 were deemed positive. Results: 714 HCWs, 487 women (68.2%), were included in our study. The mean age of the participants was 35.9 ± 8.4 (min:18, max: 62). 370 (51.8%) HCWs's the antibody level was negative, and 344 (48.2%) was positive. While 47.1% (n=122) of the HCWs with positive RT-PCR were antibody positive, 48.8% (n=222) were negative. There was no statistically significant difference in mean age and age groups (p values ​​0.338 and 0.414, respectively). Also, there was no statistically significant difference in antibody levels by gender (p=0.236). There was no significant difference between antibody positivity according to the presence of comorbidity, and the risk area studied (p=0.556, p=0.335, respectively). There was a statistically significant difference between lung involvement and antibody positivity during Covid-19 infection (p= <0.001). Conclusion: In our study, the seroprevalence of SARS-CoV-2 antibodies in HCWs was higher than the average population and approximately fifty percent. Multicenter studies with more HCWs would be helpful to determine overall seroprevalence rates

In ovo given sunset yellow adversely affects embryonic development of chick thymus and bursa Fabricii as evidenced by histological and enzyme histochemical findings

Abstract Background Sunset yellow (E110) has largely been used as food coloring agent. Complaints accumulated on E110 for possible detrimental effects on the immune functions such as allergenicity in the children. In this study, the effects of different doses of E110 on embryonic development of chicken primary lymphoid organs, thymus and bursa of Fabricius were determined by means of histological, histomorphometrical and histochemical methods. A total of 250 fertilized eggs from the Ross 508 line were used in the study. The eggs were divided into 5 groups as non-treated, sham-exposed and 100 ng/egg, 500 ng/egg, 1000 ng/egg E110-injected groups, each having 50 eggs. Results In the 1.000 ng/egg E110-administered group, embryonic development of chicken thymus and bursa of Fabricius were retarded. Conclusions E110 given in ovo before incubation retarded the embryonic development of the avian thymus and bursa of Fabricii. The effect is more pronounced in the 1.000 ng/egg group

From asymptomatic to critical illness: Decoding various clinical stages of COVID-19

The clinical course of COVID-19 is variable, with clinical manifestation ranging from 81% mild course to 14% severe course along with 5% critical course in patients. The asymptomatic course is reported to potentially range between 20% and 70% (avg. 33%). A more severe course is seen in the elderly, those with various chronic diseases, and the immunosuppressed, where the case fatality rate is higher in these risk groups. The disease progresses with various symptoms, such as fever, cough, shortness of breath, malaise, myalgia, taste and smell disorders, diarrhea, sore throat, headache, and conjunctivitis. The disease begins with shortness of breath, indicative of lung damage, after an average of 7 to 10 days, and progresses in ARDS, sepsis, and septic shock. Some patients quickly enter shortness of breath, while others gradually develop shortness of breath and chest tightness and burning. The risk factors for a poor prognosis are age, comorbidities, and changes in laboratory tests. Secondary bacterial and fungal infections frequently develop with steroids and immunosuppressants, especially in the intensive care unit. Frequent complications in hospitalized patients include pneumonia (75%), ARDS (15%), acute renal failure (9%), and acute liver injury (19%). An increased incidence of heart damage is observed, including acute heart failure, arrhythmias, and myocarditis. Of the patients hospitalized due to COVID-19, 10%-25% present with prothrombotic coagulopathy, resulting in venous and arterial thromboembolic events. The most common extrapulmonary symptom is neuropsychiatric involvement, frequently accompanied by insomnia, an impediment to remembering, and an altered state of consciousness. During the course of COVID-19, patients undergo some pathological changes (severe lymphopenia, high levels of C-reactive protein, D-dimer, ferritin, etc.) depending on the condition and exposure level of the affected systems as shown by various laboratory tests. The relevant tests are the guiding elements of risk assessment, clinical monitoring, disease severity, and prognosis setting and therapy decision processes

A case of splenic infarction associated with brucellosis which resolved with antimicrobial treatment.

Brucellosis is an unusual cause of splenic infarction. Only a few cases have been reported worldwide, mostly associated with brucellosis. Herein, we reported a 36-year-old animal-husbandry woman having a splenic infarction associated with brucellosis. She applied to the emergency department with complaints of fever, chills, weight loss, nausea, vomiting and arthralgia. Her laboratory findings included leukopenia, anemia, and elevated liver enzymes. Abdominal computerized tomography revealed splenic infarction. Brucella standard tube agglutination test was 1/160. Brucella melitensis was grown in blood culture in the seventh day of hospitalization. The patient was commenced on doxycycline and streptomycine.</div